The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 28, 2015

Filed:

May. 03, 2006
Applicants:

Marisol Corral-debrinski, Montreuil, FR;

Jose-alain Sahel, Paris, FR;

Valerie Kaltimbacher, Fontenay Sous Bois, FR;

Crystel Bonnet, Montrouge, FR;

Inventors:

Marisol Corral-Debrinski, Montreuil, FR;

Jose-Alain Sahel, Paris, FR;

Valerie Kaltimbacher, Fontenay Sous Bois, FR;

Crystel Bonnet, Montrouge, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/63 (2006.01); C07H 21/00 (2006.01); C12N 5/00 (2006.01); C12N 15/85 (2006.01); A61K 48/00 (2006.01); C12N 9/02 (2006.01);
U.S. Cl.
CPC ...
C12N 15/8509 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); C07K 2319/07 (2013.01); C12N 9/0053 (2013.01); C12N 9/0089 (2013.01); C12N 15/85 (2013.01); C12N 2810/80 (2013.01); C12Y 109/03001 (2013.01); A61K 48/0066 (2013.01);
Abstract

The inventors demonstrate that mRNA sorting to the mitochondrial surface is an efficient way to proceed to such an allotopic expression, and that this mRNA sorting can be controlled by selecting appropriate mitochondrion-targeting sequence (MTS) and appropriate 3'UTR sequences. The CDS sequence which codes for the protein to be delivered into the mitochondrion is guided by these appropriate MTS and 3′UTR sequences from the nuclear compartment to the mitochondrion-bound polysomes (where the CDS is translated), and aids in an efficient translocation of a mature functional protein into the mitochondria. Appropriate MTS and 3′UTR sequences correspond to those of nuclearly-transcribed mitochondrially-targeted mRNAs. The inventors demonstrate that, to obtain a stable therapeutically-effective importation, both an appropriate MTS and an appropriate 3′UTR should preferably be used.


Find Patent Forward Citations

Loading…